iSpecimen (ISPC) Net Income towards Common Stockholders (2020 - 2026)

iSpecimen's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 46.26% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$10.5 million (up 17.56% YoY), while the FY2025 annual figure was -$9.7 million, up 31.84% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.7 million, up from -$2.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$1.7 million in Q3 2024, with the low at -$6.3 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$2.8 million (2025), against an average of -$2.9 million.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 110.81% in 2022, then jumped 54.46% in 2025.
• iSpecimen's Net Income towards Common Stockholders stood at -$2.1 million in 2022, then slumped by 52.1% to -$3.2 million in 2023, then plunged by 99.1% to -$6.3 million in 2024, then soared by 54.46% to -$2.9 million in 2025, then increased by 7.65% to -$2.7 million in 2026.
• Business Quant data shows ISPC's Net Income towards Common Stockholders at -$2.7 million in Q1 2026, -$2.9 million in Q4 2025, and -$2.8 million in Q3 2025.